approach to the patient with esophageal cancer: the intent of the surgeon to either cure or palliate, the anatomic location of the tumor, and the method of reconstruction. Surgery is optimal for localized esophageal cancer. Neoadjuvant chemoradiation has increased survival in specific subgroups. Phase 2 trials have shown the safety and efficacy of chemoradiation. Randomized multi-institutional trials are needed to verify the encouraging results of recent phase 2 trials.
(CHEST 1995; 107:218S-223S)
Manual for Staging of Cancer. 4 The new system is based on depth of wall penetration and lymph node involvement, these two variables being most predictive of long-term survival. TINOMO   T2-T3, NOMO  TI-T2, NIMO  T3N1MO or T4 such protocols will ultimately affect the dismal survival rates reported in this disease over the past 30 years.
Computed Tomography and Magnetic Resonance

Imaging
Computed tomographic scan of the chest and upper abdomen with oral and intravenous contrast is used to evaluate the primary esophageal tumor, supraclavicular nodes, mediastinal nodes, abdominal nodes, lungs, liver, and adrenal glands. Compared with resection specimens, the accuracy of CT images is 80 to 85% in detecting extent of disease. [5] [6] [7] [8] [9] Evaluation of the primary tumor by CT scan is not without limitations. Individual layers of the esophageal wall cannot be discerned with certainty. A wall thickness greater than 5 mm is equated with at least a T2 tumor, and T4 lesions (involving adjacent organs) are difficult to diagnose with certainty.5
Computed tomographic accuracy of regional lymph node status is less than 69%.10,11 Radiologic criteria for an abnormal lymph node is a transverse axis of 10 mm or greater. Nodes less than 10 Endoesophageal ultrasound is a relatively new instrument used for staging. It consists of a probe at the end of an endoscope and an inflatable balloon to distend the esophagus and provide an ultrasonic interface between the probe and the mucosa.5
Endoesophageal ultrasound is a good tool for the detection of depth of tumor invasion. It has a broad range of accuracy, ranging from 71% overall to 98% of the subset of patients without obstruction.512 '14 Endoesophageal ultrasound understages the primary tumor in about 5% of cases and overstages the primary tumor in approximately 6 to 11%,12,14 especially in tumors that do not extend through the muscularis propria.
Unlike CT, EUS can assess the shape, margin, and internal structure, as well as the size, of mediastinal and celiac nodes. However, it has been difficult to distinguish inflammatory lymph nodes from metastatic disease by EUS. Quantification of EUS accuracy for node status has generally ranged between 70 and 88%.5,1214 Although highly sensitive (85 to 95%), the accuracy of predicting the status of lymph nodes is adversely affected by a low specificity (50 to 60%). 12, 14 At present, EUS fails to fully visualize the abdominal extent of disease secondary to obstruction of the esophagus in a significant number of patients (21 to 36%). The ultrasonic endoscope is large and cannot be passed through stenotic lesions.'1315
Approximately 66% of patients presenting with esophageal cancer will have abnormal regional lymph nodes.16 With the encouraging results of new induction chemotherapy and radiotherapy (RT) protocols, the preresectional identification of this group has become important.
Recent advances in thoracoscopy have opened new vistas for surgical staging of esophageal cancer. Thoracoscopy allows evaluation of the entire thoracic esophagus and periesophageal nodes in the right side of the chest, and the aortopulmonary window nodes, periesophageal nodes, and mid-to-lower thoracic esophagus in the left side of the chest. Occult pleural and pulmonary metastases can be readily identified at thoracoscopy. The minimally invasive surgical staging procedure allows direct visualization of the adventitia of the esophagus and can accurately judge deep wall invasion and involvement of adjacent organs. The location and nature of contiguous spread to important adjacent mediastinal structures can be directly assessed. Regional lymph nodes can be visualized and directly sampled for histologic analySiS.
Thoracoscopy can be combined with staging abdominal laparoscopy or minilaparotomy under the same general anesthetic. In a systematic fashion, the peritoneal surface, liver, gastrohepatic ligament, gastric wall, cardia, and undersurface of the diaphragm are inspected. Biopsy specimens are taken from the celiac nodes and perigastric nodes, even when they appear completely normal. Patients deemed candidates for multimodality protocols can then have a central venous catheter port and feeding jejunostomy placed at the end of the staging procedures.
The main advantage of the combined thoracoscopic/laparoscopic staging procedure is that it provides greater accuracy in evaluation of regional and celiac lymph nodes. Such information is indispensable in patient stratification and selection of therapy, especially in the setting of new treatment protocols. Furthermore, for patients who will be receiving RT, the histologic status of thoracic and abdominal lymph nodes is critical for the design of treatment fields. For example, in patients with tumors of the lower esophagus, the supraclavicular lymph nodes may be omitted from the treatment field in the absence of involved nodes. If thoracic nodes are involved, however, treatment fields may be increased to cover the supraclavicular regions since they would represent a high-risk site in this setting. Moreover, RT The esophagus is anatomically divided into four areas. The cervical esophagus extends from the cricopharyngeal muscle to the thoracic inlet. The upper third of the mediastinal esophagus extends to the aortic arch. The middle third continues to the inferior pulmonary vein, and the lower third connects with the gastric cardia.
Anatomic location influences the choice of surgical procedure. Tumors of the cervical esophagus are best treated with RT or a surgical approach through the right side of the neck. [26] [27] [28] Upper-third lesions of the thoracic esophagus are best approached through a right anterolateral thoracotomy. Middle-third lesions are approached through a three-hole method, with a midline laparotomy, right posterolateral thoracotomy, and left cervical incision. Primary lesions of the distal third of the thoracic esophagus can be approached through a left sixth-interspace thoracotomy with an intrathoracic gastroesophageal anastomosis, 29 
Method of Reconstruction
In general, the first choice of a conduit for reconstruction is the stomach. The stomach is converted to a tube and based on the right gastroepiploic artery. The tubular stomach has considerable length and will easily reach into the neck. It is passed through the mediastinum in the orthotopic position. There is a single anastomosis in this method of reconstruction, usually just distal to the cricopharyngeal muscle. Gastric emptying is facilitated by an accompanying pyloromyotomy or pyloroplasty. The stomach conduit provides excellent function and is associated with low morbidity.
The colon is an alternative to the stomach for reconstruction. It is based on the middle colic artery and is generally placed in a heterotopic position beneath the sternum. There are generally three anastomoses in this operation: colocolonic to reestablish the continuity of the lower gastrointestinal tract, coloesophageal proximally, and cologastric or coloenteric distally.
Surgical therapy alone has produced disappointing results in the treatment of esophageal cancer. Both local and distant recurrence are common when single-modality therapy is used. There has been great interest in the possible role of induction chemotherapy and RT which may both increase the number of curative resections and prolong survival. Careful patient selection for these protocols is needed to both tailor new treatments and to properly assess their impact.
NEOADJUVANT THERAPY Preoperative RT has been used in an attempt to improve overall results in patients with esophageal cancer.30-33 Most investigators have used 40 Gy given over 4 weeks, with surgery performed 4 weeks later. Clifton et a133 reported an increase in resectability rate from 58 to 79% with preoperative RT. This observation was confirmed by Akakura et a134 but challenged by Launois et al. 32 Preoperative RT does not seem to adversely affect operative mortality or morbidity.30-32 Most series suggest that preoperative RT helps improve local control but makes little difference in overall survival owing to the increased incidence of clinically apparent distant metastases in the radiated groups during follow-up.
Esophageal cancer has been resistant to singleagent chemotherapy with a best response rate of 15%.3 However, the discovery of an efficacious chemotherapy protocol would be helpful in this disease, which is characterized by a high frequency of occult systemic spread at the time of diagnosis.
As previously noted, aggressive surgical resection alone produces a 5-year survival rate of 15 to 35%. Curative RT palliates dysphagia for an average of only 6 months and produces a 17% 5-year survival rate. Both local and distant recurrences are common with both these single-modality therapies.
Preoperative chemotherapy combinations have been more effective than single-agent applications. Most investigators have combined cisplatin with one or more agents with response rates of 40 to 50% 35,36
Roth et al36 reported on a multi-institutional randomized trial of surgery alone (20 patients) vs a preoperative cycle of cisplatin, vindesine, and bleomycin followed by surgery (19 patients) for epidermoid cancer of the middle and lower esophagus. Patients in the chemotherapy arm were given additional cisplatin and bleomycin for 6 months postoperatively. The preoperative response rate to chemotherapy was 47% (one complete response [CR] and seven partial responses) with manageable toxic reactions. There was no difference in resectability rates or morbidity and mortality, but the patients responding to chemotherapy had a median survival advantage (>20 months compared with 8.6 months for those treated with surgery alone). The authors noted a significantly greater response in patients with less than 10% weight loss, which they interpreted as patients with less-advanced disease.
The rationale behind trimodality therapy with preoperative chemotherapy and RT is that there will be simultaneous treatment for both local and occult distant disease. Furthermore, chemotherapy is better tolerated prior to surgery than after surgery. (35 Gy) . Forty-two patients progressed to threehole esophagectomy, while 3 patients had a transhiatal esophagectomy. The 30-day operative mortality rate was 4%, and there was a 7% anastomotic leak rate. Twenty-seven percent of the patients had a pathologic CR. Median survival was 33 months. The 2-year survival rate for those patients with a pathologic CR was 74%. Patients with residual tumor in the specimen had a 2-year survival rate of 33%. There was no difference in overall 2-year survival rates based on cell type: 54% for adenocarcinoma and 53% for squamous cell carcinoma.
In this ongoing series, concomitant cisplatin/5-FU and RT have not adversely affected surgical morbidity and mortality. There has been an excellent response to induction therapy, with a trend toward improved survival in those patients responding to therapy.
CONCLUSIONS
Esophageal cancer continues to be a major health problem with an associated poor prognosis. New technology is being applied to the preresectional staging of this cancer. Accurate pathologic staging allows the identification of subgroups of patients who may benefit most from new combined-modality treatments.
Surgery is optimal for localized esophageal cancer. Neoadjuvant chemoradiation has increased survival in specific subgroups. Phase 2 trials have demonstrated the safety and efficacy of chemoradiation.
The field of neoadjuvant therapy for esophageal cancer continues to progress. Randomized multiinstitutional trials are needed to verify the encouraging results of recent phase 2 trials. Additionally, optimal combinations of chemotherapeutic agents need to be found. More importantly, a method is needed to clearly identify the subgroup of patients expected to benefit from neoadjuvant therapy.
